You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 19, 2025

Details for New Drug Application (NDA): 205232


✉ Email this page to a colleague

« Back to Dashboard


NDA 205232 describes PERPHENAZINE, which is a drug marketed by Pharm Assoc, Ani Pharms, Appco, Jubilant Generics, Macleods Pharms Ltd, Mylan, Ph Health, Rising, Sandoz, Watson Labs Inc, Wilshire Pharms Inc, Zydus Pharms, Chartwell Rx, Fosun Pharma, Ivax Sub Teva Pharms, Par Pharm, Sun Pharm Industries, and Watson Labs, and is included in fifty NDAs. It is available from sixteen suppliers. Additional details are available on the PERPHENAZINE profile page.

The generic ingredient in PERPHENAZINE is amitriptyline hydrochloride; perphenazine. There are thirteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the amitriptyline hydrochloride; perphenazine profile page.
Summary for 205232
Tradename:PERPHENAZINE
Applicant:Zydus Pharms
Ingredient:perphenazine
Patents:0
Pharmacology for NDA: 205232
Medical Subject Heading (MeSH) Categories for 205232
Antipsychotic Agents
Dopamine Antagonists
Suppliers and Packaging for NDA: 205232
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
PERPHENAZINE perphenazine TABLET;ORAL 205232 ANDA Golden State Medical Supply, Inc. 51407-694 51407-694-01 100 TABLET in 1 BOTTLE (51407-694-01)
PERPHENAZINE perphenazine TABLET;ORAL 205232 ANDA Golden State Medical Supply, Inc. 51407-695 51407-695-01 100 TABLET in 1 BOTTLE (51407-695-01)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength2MG
Approval Date:Apr 6, 2020TE:ABRLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength4MG
Approval Date:Apr 6, 2020TE:ABRLD:No

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength8MG
Approval Date:Apr 6, 2020TE:ABRLD:No

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2025 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2025 - 2026
 NCE-1 Patent Challenge Dates 2025 - 2026
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links